EP2346487A2 - Combinaison de principes actifs pour le traitement des peaux matures - Google Patents

Combinaison de principes actifs pour le traitement des peaux matures

Info

Publication number
EP2346487A2
EP2346487A2 EP09740708A EP09740708A EP2346487A2 EP 2346487 A2 EP2346487 A2 EP 2346487A2 EP 09740708 A EP09740708 A EP 09740708A EP 09740708 A EP09740708 A EP 09740708A EP 2346487 A2 EP2346487 A2 EP 2346487A2
Authority
EP
European Patent Office
Prior art keywords
skin
daltons
cosmetic
range
protein hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP09740708A
Other languages
German (de)
English (en)
Inventor
Soraya Heinen
Marianne Waldmann-Laue
Iris Marina Stadler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP2346487A2 publication Critical patent/EP2346487A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/342—Alcohols having more than seven atoms in an unbroken chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the invention relates to topical cosmetic or dermatological compositions for treating mature or intrinsically or extrinsically aged or photodamaged skin, in particular for anti-wrinkle treatment, in a suitable cosmetic or dermatological carrier, a drug combination of at least two Soyaproteinhydrolysaten with different average molecular weight distributions, at least one wheat protein hydrolyzate and at least one hydrophilic Extract of Ambrette seeds included.
  • a significant consequence of skin aging is the loss of collagen. This is based on the one hand on a reduced collagen synthesis in certain skin cells, the fibroblasts, on the other hand on an increased collagen degradation, in particular by certain enzymes, such as the so-called matrix metalloproteinase-1 (MMP-1).
  • MMP-1 matrix metalloproteinase-1
  • UV-induced expression of matrix metalloproteinase-1 results in collagen-1 degradation accounting for approximately 85% of the total protein content in the extracellular matrix.
  • other proteins provide the skin tissue with mechanical stability. These proteins mediate cell-extracellular matrix (ECM) binding. Part of the ECM is z. As the collagen or hyaluronic acid.
  • the binding of cells to ECM proteins is mediated by receptors located on the cell surface. Thus, e.g. the surface receptor CD44, whose expression is increased, for example, by apple seed extracts, to hyaluronic acid.
  • Topical compositions containing peptides that stimulate collagen synthesis are known in the art. Such compositions show some anti-wrinkle performance but as a result are not yet satisfactory. Topical skin care products with following proven anti-wrinkle performance z. As contain tretinoin or ⁇ -hydroxycarboxylic acid, are often due to the necessary higher concentrations of these drugs only moderately or even poorly tolerated by the skin. Other agents with proven anti-wrinkle performance are unstable, for example, to chemical degradation, eg. Tretinoin or flavonoids. Phytoflavones, which also have an anti-wrinkle performance, can be hormonal and are therefore less preferred for cosmetics.
  • the prior art lacks effective preparations which are able to repair existing aging-related deficits, in particular in the area of the extracellular matrix.
  • compositions for the topical treatment of the skin in a suitable cosmetic or dermatological carrier, at least one soy protein hydrolyzate having an average molecular weight in the range from 1200 to 1800 daltons, preferably in the range from 1400 to 1700 Dalton, at least one soy protein hydrolyzate having an average molecular weight in the range of 600 to 1000 daltons, preferably 800 daltons, at least one wheat protein hydrolyzate and at least one hydrophilic extract of ambrette seeds, which obviates the disadvantages of the prior art, and compositions for treatment mature or intrinsic or extrinsically aged skin, in particular for anti-wrinkle treatment, which synergistically enhances and improves their effects on wrinkle smoothing and skin appearance improvement over prior art compositions become T.
  • compositions containing, in a suitable cosmetic or dermatological carrier, at least one soy protein hydrolyzate having an average molecular weight in the range of 1200-1800 daltons, preferably in the range 1400-1700 daltons, at least one soy protein hydrolyzate having an average molecular weight in the range of 600-1000 daltons, preferably 800 daltons, at least one wheat protein hydrolyzate and at least one hydrophilic extract of ambrette seeds an effective anti-wrinkle treatment with improved skin tolerance can be made.
  • the present invention relates to cosmetic or dermatological compositions for the topical treatment of the skin, in a suitable cosmetic or dermatological carrier a) at least one soy protein hydrolyzate having an average molecular weight in the range of 1200 to 1800 daltons, preferably in the range of 1400 to 1700 daltons. at least one Soy protein hydrolyzate having an average molecular weight in the range of 600-1000 daltons, preferably 800 daltons, c) at least one wheat protein hydrolyzate and d) at least one hydrophilic extract of ambrette seeds.
  • An inventively particularly preferred soy protein hydrolyzate having an average molecular weight (Mw) in the range of 1200 to 1800 daltons, preferably in the range of 1400 to 1700 daltons (Da), is available under the trade name Ridulisse C from Silab.
  • the protein hydrolyzate content in Ridulisse C contains four molecular weight fractions: 0.8% by weight with a Mw> 12,500 Da, 22.2% by weight with 1355 Da ⁇ Mw ⁇ 12,500 Da, 43.1% by weight 75 Da ⁇ Mw ⁇ 1355 Da and 33.9 wt% ⁇ 75 Da.
  • the interaction between the extracellular matrix (ECM) and the fibroblasts is understood to mean both the interaction between the collagen of the ECM and the fibroblasts and the interaction between the hyaluronic acid of the ECM and the fibroblasts.
  • compositions according to the invention are characterized in that they contain at least one soy protein hydrolyzate having an average molecular weight (Mw) in the range from 1200 to 1800 daltons, preferably in the range from 1400 to 1700 daltons, in a total amount of 0.0001 to 5 wt .-%, preferably 0.001 to 1 wt .-%, particularly preferably 0.01 to 0.1 wt .-% and most preferably 0.02 to 0.05 wt .-%, in each case based on the content of active substance in the whole composition.
  • Mw average molecular weight
  • a particularly preferred soy protein hydrolyzate according to the invention having an average molecular weight in the range from 600 to 1000 daltons, preferably 800 daltons, is obtainable from Coletica under the trade name phytokines. It stimulates collagen synthesis.
  • Cosmetic or dermatological compositions which are particularly preferred according to the invention are characterized in that they contain at least one soy protein hydrolyzate having an average molecular weight (Mw) in the range from 600 to 1000 daltons, preferably 800 daltons, in a total amount of 0.0001 to 1% by weight 0.001 - 0.1 wt .-%, more preferably 0.005 - 0.05 wt .-% and most preferably 0.006 - 0.01 wt .-%, in each case based on the content of active substance in the total composition.
  • Mw average molecular weight
  • a particularly preferred wheat protein hydrolyzate according to the invention is available under the trade name Liftiline from Silab.
  • compositions according to the invention are characterized in that they contain at least one wheat protein hydrolyzate in a total amount of 0.001-5.0% by weight, preferably 0.01-1.0% by weight, more preferably 0.1-0 , 5 wt .-% and most preferably 0.2 to 0.4 wt .-%, in each case based on the content of active substance in the total composition.
  • compositions according to the invention contain at least one hydrophilic extract of ambrette seeds.
  • hydrophilic extract is understood according to the invention to mean an extract of ambrette seed which has been extracted with a hydrophilic solvent selected from water, ethanol, at least one polyhydric alcohol having 2 to 9 carbon atoms and / or at least one water-soluble polyethylene glycol 3-20 ethylene oxide units which are liquid under normal conditions
  • a hydrophilic solvent selected from water, ethanol, at least one polyhydric alcohol having 2 to 9 carbon atoms and / or at least one water-soluble polyethylene glycol 3-20 ethylene oxide units which are liquid under normal conditions
  • Preferred polyhydric alcohols having 2 to 9 carbon atoms which are liquid under normal conditions are selected from ethylene glycol, 1,2-propylene glycol, 2-methyl-1,3 Propanediol, glycerol, 1, 2-butylene glycol, 1, 3-butylene glycol and 1, 4-butylene glycol, pentylene glycols, such as 1, 2-pent
  • Preferred water-soluble polyethylene glycols having 3 to 20 ethylene oxide units which are liquid under normal conditions are selected from PEG-3, PEG-4, PEG-6, PEG-7, PEG-8, PEG-9, PEG-10, PEG- 12, PEG-14, PEG-16, PEG-18 and PEG-20 and mixtures thereof, with PEG-3 to PEG-8 being particularly preferred.
  • Particularly preferred hydrophilic solvents are selected from water, 1, 3-butylene glycol, 1, 2-propylene glycol, 1, 2-butylene glycol, 1, 4-butylene glycol, ethanol and mixtures thereof. Exceptionally preferred hydrophilic solvents are selected from water as well as mixtures of water and 1,3-butylene glycol.
  • Preferred hydrophilic extracts of ambrette seeds according to the invention are obtained from pressed and / or ground and / or de-oiled ambrette seeds.
  • the hydrophobic extracts of ambrette seeds according to the invention contain, based in each case on the dry substance, 1 to 100% by weight, preferably 2 to 80% by weight, more preferably 5 to 60% by weight and most preferably 10 to 50% by weight. -% peptides with 2-10 amino acid units and / or proteins.
  • the hydrophobic extracts of ambrette seed according to the invention provide protection against degradation of the fibroblast growth factor (FGF-2 or basic FGF or FGF-ß).
  • FGF-2 fibroblast growth factor
  • Numerous growth factors are responsible for the physiological processes in the skin, especially FGF-2, which has a broad spectrum of activity.
  • FGF-2 controls the proliferation of fibroblasts, which in turn facilitates the synthesis of extracellular matrix (ECM) macromolecules such as proteoglycans, glycosaminoglycans such as chondroitin sulfates, keratan sulfate, and hyaluronic acid, as well as collagens, elastin, fibrillin, and laminin that are essential for the integrity of the skin.
  • ECM extracellular matrix
  • Heparan sulfate-containing proteoglycans of ECM bind FGF-2 and thus regulate its availability or protect the growth factor from degradation by proteolysis.
  • FGF-2 is present in several isoforms. In vertebrates, there are five isoforms with molecular weights of 18; 22; 22.5; 24 and 34 kDa known. Only the 18 kDa form occurs outside the cells, the others are enclosed inside the cell, more precisely in the nucleus. Although FGF-2 is present in the organism in such abundance that it can be purified and characterized, its Messenger RNA not detectable. This fact, and the peculiarity that it is intimately distributed to the basement membrane of the tissues, suggests that it is produced at an initial rate and then released by the cells during development to be stored in the ECM. This storage, if needed, allows FGF-2 release in the adult state to participate in tissue repair and maintain differentiated functions.
  • compositions according to the invention contain at least one hydrophilic extract of ambrette seeds.
  • Particularly preferred cosmetic or dermatological compositions according to the invention are characterized in that they contain at least one hydrophilic extract of ambrette seeds in a total amount of 0.0001-0.5% by weight, preferably 0.001-0.1% by weight, more preferably 0.005-0.05% by weight and most preferably 0.01-0.04% by weight, based in each case on the content of active substance in the entire composition.
  • compositions according to the invention are characterized in that they contain a) at least one soy protein hydrolyzate having an average molecular weight in the range from 1200 to 1800 daltons, preferably in the range from 1400 to 1700 daltons, b) at least one soy protein hydrolyzate having an average molecular weight in the range from 600 to 1000 daltons, preferably 800 daltons, c) at least one wheat protein hydrolyzate and d) at least one hydrophilic extract from ambrette seeds in weight ratios of 1: (0.1-1) :( 1-50): (0.1- 1), preferably 1: (0.2-0.6) :( 10-20) :( 0.3-0.5).
  • the protective effect of the hydrophilic extract from ambrette seeds is particularly noticeable in long-term use.
  • compositions which are preferred according to the invention are characterized in that, in addition to the active substance combination of the active ingredients a) to d), they contain at least one further active ingredient which stimulates collagen synthesis and is selected from
  • Hydroxyproline which is N-acylated and esterified with two, preferably linear, C 2 -C 22 -fatty acid residues, in particular dipalmitoylhydroxyproline, the tripeptides Gly-His-Lys, Lys-Val-Lys, Lys-Val-Dab, Lys- Phe-Lys, Lys-Ile-Lys, Dab-Val
  • Lys, Lys-Val-Orn, Lys-Val-Dap, Dap-Val-Lys and Gly-His-Arg the tetrapeptides Gly-Gln-Pro-Arg (Rigin), Gly-Gln-Arg-Pro, Val-Val Arg-Pro, Rigin-Analoga and ALAMCAT Tetrapeptides, the pentapeptide Lys-Thr-Thr-Lys-Ser, the hexapeptides Val-Gly-Val-Ala-Pro-Gly, Ala-Asp-Leu-Lys-Pro-Thr (hexapeptide-3), hexapeptide-4, hexapeptide-5, hexapeptide-6, hexapeptide-8, hexapeptide-9 and hexa-peptide-10, which is at least one, preferably linear, C 2 -C 22 -fatty acid N-acylated and / or esterified derivatives of said tri-,
  • Extracts from oat grains (Avena Sativa (Oat) Kernel Extract), green tea extracts (Camellia Sinensis), creatine, as well as mixtures of the aforementioned substances.
  • the external appearance of the skin is further improved.
  • the moisture content of the skin can thus be increased.
  • the amino acids and peptides used as active ingredient are N-acylated and / or esterified to improve the penetration into the skin with at least one, preferably linear, C 2 -C 22 fatty acid.
  • Particularly preferred for N-acylation and / or esterification are C 8 -C 18 -fatty acids, very particular preference is given to myristic acid (C 14 ) and palmitic acid (C 16 ).
  • It is furthermore particularly preferred that all the amino acids and peptides used are N-acylated and / or esterified in this way. Also preferred is the substitution of the amino acids and peptides with a benzyloxycarbonyl group at the terminal amino group.
  • Cosmetic or dermatological compositions which are particularly preferred according to the invention are characterized in that, in addition to the combination of active ingredients a) to d), they comprise at least one active substance which stimulates collagen synthesis in a total amount of 0.000001 to 5% by weight, preferably 0 , 00001 - 2 wt .-%, particularly preferably 0.0001 - 1% by weight and most preferably 0.005 - 0.5 wt .-%, in each case based on the content of active substance in the total composition.
  • compositions are characterized in that they in addition to the active ingredient combination of the Active ingredients a) to d) contain at least one active substance which increases and / or improves the interaction between the extracellular matrix and the fibroblasts and which is selected from coconut fatty acid N-acylated and / or esterified soy protein hydrolyzates in the form of their alkali metal salts, preferably in the form of potassium salts,
  • Ascorbic acid the esters of ascorbic acid with inorganic and / or organic
  • Acids the ethers of ascorbic acid with mono-, oligo- and polysaccharides and the physiologically tolerated salts of these components,
  • Grape Seed Extracts (Vitis vinifera (Grape) Seed Extract), which are preferred from the
  • Hydroxystilbenes and their esters in particular resveratrol and / or resveratrol mono-,
  • Keratin hydrolysates in particular wool keratin hydrolysates
  • Conchiolinhydrolysaten the dipeptide L-Citrullyl-L-arginine and its with at least one, preferably linear, C 2 -
  • the external appearance of the skin is further improved.
  • the nutrient supply of the skin cells can thus be increased, so that further active ingredients are better absorbed into the skin and show improved efficacy.
  • compositions according to the invention are characterized in that they contain at least one extra apple kernel in amounts of 0.001-2% by weight, preferably 0.01-1.6% by weight and more preferably 0.03-1 Wt .-%, each based on the content of active substance in the total composition included.
  • agents which are preferred according to the invention and increase and / or improve the interaction between the extracellular matrix and the fibroblasts are selected from hydroxystilbenes and their esters, in particular resveratrol (trans-stilbene-3,4'-5-triol) and / or resveratrol mono- , -di- and -triphosphorklareestern and their salts.
  • An inventively particularly preferred Resveratrolphosphorklareester is trisodium resveratrol triphosphates.
  • the isoflavones include the isoflavones and the isoflavone glycosides.
  • isoflavones are to be understood as substances which are hydrogenation, oxidation or substitution products of 3-phenyl-4H-1-benzopyran, it being possible for hydrogenation to be in the 2,3-position of the carbon skeleton, oxidation to form a carbohydrate. nyloli in the 4-position may be present, and by substitution of the replacement of one or more hydrogen atoms by hydroxy or methoxy groups to understand.
  • the isoflavones preferred according to the invention include, for example, daidzein, genistein, prunetin, biochanin, orobol, santal, pratense, irigenin, glycitein, biochanin A and formononetin.
  • Particularly preferred isoflavones are daidzein, genistein, glycitein and formononetin.
  • the isoflavones are glycosidically linked via at least one hydroxy group to at least one sugar.
  • Suitable sugars are mono- or oligosaccharides, in particular D-glucose, D-galactose, D-glucuronic acid, D-galacturonic acid, D-xylose, D-apiose, L-rhamnose, L-arabinose and rutinose.
  • Particularly preferred isoflavone glycosides according to the invention are daidzin and genistin.
  • the isoflavones and / or their glycosides are contained in the preparations as constituents of a substance mixture obtained from a plant, in particular a plant extract.
  • a substance mixture obtained from a plant, in particular a plant extract.
  • Such vegetable substance mixtures can be obtained in a manner familiar to the person skilled in the art, for example by squeezing or extracting from plants such as soy, in particular from soybean, red clover or chickpeas.
  • Isoflavones or isoflavone glycosides in the form of extracts obtained from soybean are particularly preferably used in the preparations according to the invention, as described, for example, under the product name Lipobelle Soyaglycone (Mibelle AG Cosmetics), Soy Protein Isolate SPI (Protein Technology International, St. Louis) or Soy Phytochemicals Concentrate SPC (Archer Daniels Midland, Decatur) are commercially available.
  • Another special The preferred isoflavonoid-rich plant extract is apple kernel extra kt, in particular the commercial product Ederline from Seporga. Ederline contains phytohormones, isoflavonoids, phytosterols, triterpenoids, tocopherols and natural waxes.
  • Cosmetic or dermatological compositions which are particularly preferred according to the invention are characterized in that they contain at least one isoflavonoid in total amounts of 0.00001-1% by weight, preferably 0.0005-0.5% by weight and more preferably 0.001-0.1% by weight .-%, each based on the Isoflavonoiditsubstanz in the entire cosmetic composition.
  • Another active ingredient preferred according to the invention which increases and / or improves the interaction between the extracellular matrix and the fibroblasts, is dihydroquercetin (3,3 ', 4', 5,7-pentahydroxyflavanone), which is also referred to as taxifolin.
  • compositions according to the invention are characterized in that they contain at least one active substance which increases and / or improves the interaction between the extracellular matrix and the fibroblasts, in a total amount of 0.000001-10% by weight, preferably 0, 00001 - 5 wt .-%, particularly preferably 0.0001 - 2 wt .-% and most preferably 0.005 - 0.5 or 1 wt .-%, in each case based on the content of active substance in the total composition.
  • compositions according to the invention for the topical treatment of the skin in a suitable cosmetic or dermatological carrier a) at least one soy protein hydrolyzate having an average molecular weight in the range of 1200 to 1800 daltons, preferably in the range of 1400 to 1700 daltons, b) at least a soy protein hydrolyzate having an average molecular weight in the range of 600 to 1000 daltons, preferably 800 daltons, c) at least one wheat protein hydrolyzate and d) at least one hydrophilic extract of ambrette seeds, are characterized in that they further contain at least one cosmetic active ingredient is selected from
  • the monomers of the amino acids and / or the NC 2 -C 24 -acylamino acids, which are different from the obligatory active ingredients a) to d), are preferably selected from alanine, arginine, asparagine, aspartic acid, canavanine, citrulline, cysteine, cystine, desmosine , Glutamine, glutamic acid, glycine, histidine, homophenylalanine, hydroxylysine, isodesmosine, isoleucine, leucine, lysine, methionine, methylnorleucine, ornithine, phenylalanine, proline, pyroglutamic acid, sarcosine, serine, taurine, threonine, thyroxine, tryptophan, tyrosine, valine, zinc
  • the C 2 -C 24 -acyl radical with which all of the abovementioned amino acids and oligopeptides (including the obligatory active substances) can be derivatized at the amino group, is selected from an acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoyl , Octanoyl, nonanoyl, decanoyl, undecanoyl, lauroyl, tridecanoyl, myristoyl, pentadecanoyl, cetoyl, palmitoyl, stearoyl, elaidoyl, arachidoyl or behenoyl radical.
  • C 8 -C 8 -acyl radicals are also referred to as cocoyl radical and are likewise preferred substituents.
  • a particularly preferred acyl radical according to the invention which effects a particularly high availability of the acylated active substance is the palmitoyl radical.
  • physiologically acceptable salts of the inventively preferred active ingredients containing acid groups and can form salts are selected from the ammonium, alkali metal, magnesium, calcium, aluminum, zinc and manganese salts. Preferred are the sodium, potassium, magnesium, aluminum, zinc and manganese salts.
  • Preferred oligomers of the amino acids and / or the NC 2 -C 24 -acylamino acids are selected from di-, tri-, tetra-, penta-, hexa- or pentadecapeptides which may be N-acylated and / or esterified.
  • N-acylated and / or esterified dipeptides are Tyr-Arg (dipeptide-1), Val-Trp (dipeptide-2), Asn-Phe, Asp-Phe, N-palmitoyl-.beta.-Ala-His, N Acetyl-Tyr-Arg-hexyldecyl ester (eg Calmosensine from Sederma), carnosine ( ⁇ -Ala-His) and N-palmitoyl-Pro-Arg.
  • Tyr-Arg dipeptide-1
  • Val-Trp dipeptide-2
  • Asn-Phe Asp-Phe
  • N-palmitoyl-.beta.-Ala-His N Acetyl-Tyr-Arg-hexyldecyl ester (eg Calmosensine from Sederma), carnosine ( ⁇ -Ala-His) and N-palmitoyl-Pro-Arg.
  • N-acylated and / or esterified tripeptides are Lys-Pro-Val, Tyr-Tyr-Val, Tyr-Val-Tyr, Val-Tyr-Val (Tripeptide-2), Tripeptide-4 (e.g. ATPeptides, available via IMPAG), His-Ala-Orn and N-acetyl-Arg-Lys-Arg-NH 2 .
  • N-acylated and / or esterified Pentapeptides N-palmitoyl-Tyr-Gly-Gly-Phe-Met, Val-Val-Arg-Pro-Pro, N-palmitoyl-Tyr-Gly-Gly-Phe-Leu, Gly-Pro-Phe-Pro-Leu and N -Benzyloxycarbonyl-Gly-Pro-Phe-Pro-Leu (the latter two are serine proteinase inhibitors for the inhibition of desquamation).
  • Preferred, optionally N-acylated and / or esterified hexapeptides according to the invention are Ala-Arg-His-Leu-Phe-Trp (hexapeptide-1), acetyl hexapeptide-1 (eg modulenes from Vincience), acetyl glutamyl hexapeptide-1 (cf.
  • hexapeptide-2 eg, Vincan's melanostatine-DM
  • Val-Val-Arg-Pro-Pro-Pro Ala-Arg-His-methylnorleucine-homophenylalanine-Trp
  • Hexapeptides-1 1 eg, Peptamide-6 from Arch Personal Care
  • An inventively particularly preferred pentadecapeptide is z. As the raw material Vinci 01 by Vincience (Pentadecapeptide-1).
  • DNA repair enzymes preferred according to the invention are photolyase and T4 endonuclease V, the latter being abbreviated to "T4N5" below. These two enzymes are already known in the art as so-called DNA repair enzymes. DNA repair is defined as the cleavage or removal of UV-induced pyrimidine dimers from the DNA.
  • Photolyase is the abbreviation for deoxyribodipyrimidine photolyase or DNA photolyase, an enzyme with the classification number EC 4.1.99.3.
  • a particularly efficient photolyase is derived from Anacystis nidulans, a phototrophic marine microorganism. The photolyase from A. nidulans is now obtained in technically relevant quantities from E. coli. Photolyase relies on light for activation.
  • T4 endonuclease V is produced by the cfenV gene of bacteriophage T4 and is one of the phosphodiesterases that hydrolytically cleave the nucleic acids at the (5 ' -3> bond.
  • T4N5 is also active without the influence of light.
  • Liposome-encapsulated DNA repair enzymes are commercially available for.
  • the monomers and oligomers of amino acids, NC 2 -C 24 -acylamino acids, the esters and / or the physiologically acceptable metal salts of these substances are present in supported form, in particular applied to finely divided, powdery substrates such as silica gel , in particular Aerosil types, furthermore talc, microsponges, modified starches and starch derivatives, crystalline cellulose, cellulose powders, lactoglobulin derivatives, polymer particles of nylon, polyolefins, polycarbonates, polyurethanes, polyacrylates, (meth) acrylate or (meth) acrylate-vinylidene copolymers, which may be crosslinked, polyesters, polyamides, polystyrenes, Teflon and silicones.
  • a particularly preferred raw material of this type are the Vegetal Filling Spheres of Coletica.
  • compositions are characterized in that they contain at least one cosmetic active ingredient which is selected from DNA oligonucleotides and RNA oligonucleotides.
  • an oligonucleotide is understood as meaning polymers of from 2 to 20, preferably from 2 to 10, mononucleotides which, like polynucleotides and nucleic acids, are linked by phosphoric diester bridges.
  • the nucleotides consist of nucleobases (usually pyrimidine or purine derivatives), pentoses (usually D-ribofuranose or 2-deoxy-D-ribofuranose in ß-N-glycosidic bond to the nucleobase) and phosphoric acid.
  • the mononucleotides are, for example, adenosine phosphates, cytidine phosphates, guanosine phosphates, uridine phosphates and thymidine phosphates, in particular CMP (cytidine 5'-monophosphate), UDP (uridine 5'-diphosphate), ATP (adenosine 5-triphosphate) and GTP (guanosine-5 'triphosphate).
  • An oligonucleotide particularly preferred according to the invention is the thymidine dinucleotide.
  • the DNA oligonucleotides or RNA oligonucleotides are present in amounts of 0.00001-5% by weight, preferably 0.0001-1.0 Wt .-% and particularly preferably 0.0005 - 0.5 wt .-%, based on the total composition.
  • compositions are characterized in that they further contain at least one cosmetic active ingredient which is selected from at least one vitamin, provitamin or a vitamin precursor designated as a vitamin precursor from the vitamin groups A, B, C and E, the esters and the salts of the aforementioned substances.
  • RAR retinoid acid receptor
  • RXR retinoid X receptor
  • Synthetic retinoids are classified into three groups: non-aromatic (eg, isotretinoin), monoaromatic (eg, acitretin), and polyaromatic (so-called arotinoids, eg, tazarotene, which have a specific effect on single retinoid receptors).
  • non-aromatic eg, isotretinoin
  • monoaromatic eg, acitretin
  • polyaromatic so-called arotinoids, eg, tazarotene, which have a specific effect on single retinoid receptors.
  • arotinoids eg, tazarotene, which have a specific effect on single retinoid receptors.
  • Particularly preferred compounds according to the invention from the vitamin group A are retinol and the C 2 -C 22 -fatty acid esters of retinol, in particular retinyl palmitate and retinyl acetate.
  • Vitamin B 1 Vitamin B 1, thiamine trivial name, chemical designation 3 - [(4 '-amino-2' -methyl-5 '-pyrimidi- nyl) methyl] -5- (2-hydroxyethyl) -4-methylthiazolium chloride.
  • Thiamine hydrochloride is preferably used in amounts of from 0.05 to 1% by weight, based on the total composition.
  • Vitamin B 2 common name riboflavin, chemical name 7,8-dimethyl-10- (1-D-ribityl) - benzo [g] pteridine-2,4 (3 / - /, 10 / - /) - dione.
  • Riboflavin or its derivatives are preferably used in amounts of from 0.05 to 1% by weight, based on the total composition.
  • the compounds nicotinic acid and nicotinamide are performed.
  • Preferred according to the invention is the nicotinic acid amide, which is preferably present in the compositions according to the invention in amounts of from 0.05 to 1% by weight, based on the total composition.
  • pantothenic acid and panthenol Panthenol is preferably used.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols.
  • derivatives of 2-furanone instead of and in addition to pantothenic acid or panthenol, it is also possible to use derivatives of 2-furanone having the general structural formula (VIT-I).
  • the substituents R 1 to R 6 independently of one another are a hydrogen atom, a hydroxyl radical, a methyl, methoxy, aminomethyl or hydroxymethyl radical, a saturated or mono- or diunsaturated, linear or branched one C 2 -C 4 -hydrocarbon radical, a saturated or mono- or diunsaturated, branched or linear mono-, di- or trihydroxy-C 2 -C 4 -hydrocarbon radical or a saturated or mono- or diunsaturated, branched or linear mono , Di- or triamino-C 2 -C 4 - hydrocarbon radical.
  • Particularly preferred derivatives are the commercially available substances dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone with the trivial name pantolactone (Merck), 4-hydroxymethyl- ⁇ -butyrolactone (Merck), 3 , 3-Dimethyl-2-hydroxy- ⁇ -butyrolactone (Aldrich) and 2,5-dihydro-5-methoxy-2-furanone (Merck), expressly including all stereoisomers.
  • the extremely preferred 2-furanone derivative according to the invention is pantolactone (dihydro-3-hydroxy-4,4-dimethyl-2 (3H) -furanone), where in formula (I) R 1 is a hydroxyl group, R 2 is a hydrogen atom, R 3 and R 4 represent a methyl group and R 5 and R 6 represent a hydrogen atom.
  • the stereoisomer (R) -pantolactone is formed during the degradation of pantothenic acid.
  • the said compounds of the vitamin B 5 type and the 2-furanone derivatives are present in the compositions according to the invention in a total amount of 0.05 to 5 wt.%, Preferably 0.1 to 3 wt.%, Particularly preferably 0.5 to 2 wt .-%, each based on the total composition included.
  • Vitamin B 6 which is understood hereunder no uniform substance, but the known under the common names pyridoxine, pyridoxamine and pyridoxal derivatives of 5-hydroxymethyl-2-methylpyridin-3-ols.
  • Vitamin B 6 is contained in the agents according to the invention preferably in amounts of 0.0001 to 1, 0 wt .-%, in particular in amounts of 0.001 to 0.01 wt .-%.
  • Vitamin B 7 also known as vitamin H or "skin vitamin”.
  • Biotin is (3aS, 4S, 6af?) - 2-oxohexahydrothienol [3,4-cf] -imidazole-4-valeric acid.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • Folic acid (vitamin B 9 , vitamin B c ).
  • Folate is used synonymously with pteroylglutamate.
  • Folate is the collective term for all acid-active compounds and denotes a substance class that has a 4-amino acid class. benzoic acid and L-glutamic acid associated pteridine ring.
  • Folic acid is a growth factor for various microorganisms and a compound of vitamin character, which is usually found in nature as polyglutamate and in reduced form (7,8-dihydrofolic acid, H 2 folate, DHF, tetrahydrofolic acid, H 4 folate, THF, 5'-methyl). Tetrahydrofolic acid, CH 3 -H 4 folate, MeTHF).
  • Particularly preferred compositions according to the invention are characterized in that they contain at least one component selected from folic acid, folates and their esters, in a total amount of 0.0001 to 1.0% by weight, in particular 0.01 to 0.5% by weight. %, based on the composition.
  • Orotic acid (vitamin B 13 , 1, 2,3,6-tetrahydro-2,6-dioxo-4-pyrimidine-carboxylic acid, uracil-6-carboxylic acid, molar acid).
  • Orotic acid, its choline ester or orotic acid metal salts (orotates of Ca, Cr, Fe, K, Co, Cu, Li, Mg, Mn, Na, Zn, Sn) are particularly preferred according to the invention.
  • Particularly preferred compositions according to the invention are characterized in that they contain at least one component selected from orotic acid, orotates and their esters, in a total amount of 0.0001-1.0% by weight, in particular 0.01-0.5% by weight. %, based on the composition.
  • Active ingredients which are preferred according to the invention and belong to the vitamin C group are selected from ascorbic acid, the esters of ascorbic acid with inorganic and / or organic acids, the ethers of ascorbic acid with mono-, oligo- and polysaccharides, as well as the physiologically tolerated salts of these components.
  • physiologically tolerated salts the zinc, copper and manganese salts and the salts of the alkali and alkaline earth metals, in particular the sodium, potassium, magnesium and calcium salts, are particularly preferred.
  • Particularly preferred active ingredients belonging to the vitamin C group are selected from ascorbic acid and the ascorbic acid derivatives sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbyl palmitate, disodium ascorbyl phosphate, disodium ascorbyl sulfate, sodium ascorbate, magnesium ascorbate, ascorbyl stearate, ascorbyl dipalmitate, ascorbyl acetate, potassium ascorbyl tocopheryl phosphate, chitosan ascorbate and ascorbyl glucoside.
  • ascorbic acid and the ascorbic acid derivatives sodium ascorbyl phosphate, magnesium ascorbyl phosphate, ascorbyl palmitate, disodium ascorbyl phosphate, disodium ascorbyl sulfate, sodium ascorbate, magnesium ascorbate, ascorbyl stearate, ascorbyl dipalmitate, ascorbyl acetate, potassium ascorbyl tocophe
  • the vitamin E group includes tocopherol, especially ⁇ -tocopherol, and its derivatives.
  • Preferred derivatives are in particular the esters, such as tocopheryl acetate, nicotinate, phosphate, succinate, linoleate, oleate, tocophereth-5, tocophereth-10, tocophereth-12, tocophereth-18, tocophereth-50 and tocopherol.
  • Tocopherol and its derivatives are preferably present in amounts of from 0.05 to 1% by weight, based on the total composition.
  • compositions are characterized in that they contain at least one cosmetic active ingredient which is selected from at least one ⁇ -hydroxycarboxylic acid, ⁇ -ketocarboxylic acid or ⁇ -hydroxycarboxylic acid or their ester, lactone and / or salt form.
  • Preferred ⁇ -hydroxycarboxylic acids or ⁇ -ketocarboxylic acids according to the invention are glycolic acid, lactic acid, tartaric acid, citric acid, 2-hydroxybutanoic acid, 2,3-dihydroxypropanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, 2-hydroxyheptanoic acid, 2-hydroxyoctanoic acid, 2-hydroxydecanoic acid, 2- Hydroxydodecanoic acid, 2-hydroxytetradecanoic acid, 2-hydroxyhexadecanoic acid, 2-hydroxyoctanecanoic acid, mandelic acid, 4-hydroxymandelic acid, malic acid, erytharic acid, threaric acid, glucaric acid, galactaric acid, mannaric acid, gularic acid, 2-hydroxy-2-methylsuccinic acid, gluconic acid, pyruvic acid, Glucuronic acid and galacturonic acid.
  • Particularly preferred ⁇ -hydroxycarboxylic acids are lactic acid, citric acid, glycolic acid and gluconic acid.
  • a particularly preferred ⁇ -hydroxycarboxylic acid is salicylic acid.
  • a particularly preferred ⁇ -ketocarboxylic acid is pyruvic acid.
  • the esters of said acids are selected from the methyl, ethyl, propyl, isopropyl, butyl, amyl, pentyl, hexyl, 2-ethylhexyl, octyl, decyl, dodecyl and hexadecyl esters.
  • ⁇ -hydroxycarboxylic acids, ⁇ -ketocarboxylic acids or ⁇ -hydroxycarboxylic acids or their derivatives are preferably present in a total amount of 0.1-10% by weight, more preferably 0.5-5% by weight and most preferably 1-2% by weight. -%, in each case based on the total composition included.
  • the .alpha.-hydroxycarboxylic acids, .alpha.-ketocarboxylic acids or .beta.-hydroxycarboxylic acids or their derivatives show, in interaction with the active ingredient combination a) to d) according to the invention, a surprisingly better compatibility.
  • the acid components can cause some irritative effect, especially in higher concentrations. This can be reduced by the active ingredient combination a) to d) according to the invention.
  • compositions are characterized in that they contain at least one cosmetic active ingredient which is selected from at least one flavonoid and / or at least one flavonoid-rich plant extract.
  • the flavonoids preferred according to the invention include the glycosides of the flavones, the 3-hydroxyflavones (flavonols) and the aurones.
  • the flavanones and isoflavones according to the invention are expressly excluded from the flavonoids.
  • flavonoids are selected from naringin (aurantiine, naringenin-7-rhamnoglucoside), ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercetin, ⁇ -glucosylquercetin, rutin (3,3 ', 4', 5,7-pentahydroxyflavone-3 -rhamnoglucoside, quercetin-3-rhamnoglucoside), troxerutin (3,5-dihydroxy-3 ', 4', 7-tris (2-hydroxyethoxy) -flavone-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl) - ⁇ -D-glucopyranoside)), monoxerutin (3,3 ', 4', 5-tetrahydroxy-7- (2-hydroxyethoxy) flavone-3- (6-O- (6-deoxy- ⁇ -L-mannopyranosyl)
  • Extremely preferred flavonoids according to the invention are ⁇ -glucosylrutin, naringin and apigenin-7-glucoside. Also preferred are the constructed from two flavonoid biflavonoids, z. B. in gingko species occurrence. Further preferred flavonoids are the chalcones, especially phloricin and neohespeptide dihydrochalcone.
  • the flavonoids are used in amounts of 0.0001 to 1 wt .-%, preferably 0.0005 to 0.5 wt .-% and particularly preferably 0.001 to 0.1 wt .-%, each based on the Flavo noiditsubstanz in the entire cosmetic composition.
  • the flavonoids, in conjunction with the active ingredient combination a) to d) according to the invention, have a surprisingly better antioxidant effect, which increases the antiaging performance of the flavonoids.
  • compositions are characterized in that they further contain at least one cosmetic active ingredient which is selected from at least one ubiquinone or a ubiquinol or derivatives thereof.
  • Ubiquinols are the reduced form of ubiquinones.
  • the preferred ubiquinones according to the invention have the formula (UBI-I):
  • ubiquinone of the formula (UBI-I) with n 10, also known as coenzyme Q10.
  • the ubiquinones, ubiquinols or derivatives thereof in a total amount of 0.0001 - 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0.1 wt .-%, each based on the entire composition, used.
  • the ubiquinones and ubiquinols show, in interaction with the active ingredient combination a) to d) according to the invention, a surprisingly better antioxidant effect, which increases the antiaging performance of the flavonoids.
  • silymarin is an active substance concentrate from the fruits of the milk thistle (Silybum marianum) which was previously regarded as a uniform substance.
  • the main constituents of silymarin are silybin (silymarin I), silychristin (silymarin II) and silydianin, which belong to the group of flavanolignans.
  • silymarin is used in amounts of from 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0.1 wt .-%, each based on the total composition.
  • Silymarin in conjunction with the active ingredient combination a) to d) according to the invention, has a surprisingly better antioxidant effect, which increases the antiaging performance of silymarin.
  • compositions are characterized in that they also contain ectoine.
  • Ectoin is the common name for 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylate.
  • ectoine is preferably present in amounts of from 0.0001 to 1% by weight, more preferably from 0.001 to 0.5% by weight, and most preferably from 0.005 to 0.01% by weight, based in each case on the total composition.
  • Ectoin causes in conjunction with the active ingredient combination a) to d) according to the invention a surprisingly better supply of nutrients to the cells of the skin.
  • compositions are characterized in that they further contain at least one inorganic and / or at least one organic UV filter substance.
  • the UV filter substances are substances which are liquid or crystalline at room temperature and which are capable of absorbing ultraviolet rays and of absorbing the absorbed energy in the form of longer-wave radiation, eg. B. to give off heat again.
  • the UVA and UVB filters can be used individually or in mixtures. The use of filter mixtures is preferred according to the invention.
  • the organic UV filters preferred according to the invention are selected from the derivatives of dibenzoylmethane, cinnamic acid esters, diphenylacrylic acid esters, benzophenone, camphor, p-aminobenzoic acid esters, o-aminobenzoic acid esters, salicylic acid esters, benzimidazoles, symmetrically or unsymmetrically substituted 1,3,5-triazines, monomers and oligomeric 4,4-diarylbutadiene carboxylic acid esters and carboxamides, ketotricyclo (5.2.1.0) decane, benzalmalonic acid esters, benzoxazole and any mixtures of the stated components.
  • the organic UV filters can be oil-soluble or water-soluble.
  • the benzoxazole derivatives are advantageously present in dissolved form in the cosmetic preparations according to the invention. However, it may also be advantageous if the benzoxazole derivatives are present in a pigmentary, ie undissolved form, for example in particle sizes of from 10 nm to 300 nm.
  • oil-soluble UV filters are 1- (4-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione (Parsol ® 1789), 1-phenyl-3- (4'- isopropylphenyl) -propane-1, 3-dione, 3- (4 methylbenzylidene) -D, L-camphor, A- (dimethylamino) benzoic acid 2-ethylhexyl ester, 4- (dimethylamino) benzoic acid 2-octyl ester, A Amyl (dimethylamino) benzoate, 2-ethylhexyl 4-methoxycinnamate, propyl 4-methoxycinnamate, isopentyl 4-methoxycinnamate, 2-ethylhexyl 2-cyano-3,3-phenylcinnamate (octocrylene), 2-ethylhexyl salicylate, Salicylate, Salicyl
  • Preferred water-soluble UV filters are 2-phenylbenzimidazole-5-sulfonic acid, phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and their alkali metal, alkaline earth metal, ammonium, Alkylammonium, alkanolammonium and glucammonium salts, in particular the sulfonic acid itself with the INCI name Phenylbenzimidazole Sulfonic Acid (CAS No.
  • solutions of the UV-A-filter 1 can be, for example, (4-tert-butylphenyl) - 3- (4'-methoxyphenyl) propane-1, 3-dione (such as Parsol ® 1789th) in various UV- Make B filters.
  • compositions according to the invention contain 1- (4-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione in combination with at least one UV-B filter selected from 4 2-ethylhexyl 2-methoxy cinnamic acid, 2-ethylhexyl 2-cyano-3,3-phenylcinnamate, 2-ethylhexyl salicylate and 3,3,5-trimethyl cyclohexyl salicylate.
  • UV-B filter selected from 4 2-ethylhexyl 2-methoxy cinnamic acid, 2-ethylhexyl 2-cyano-3,3-phenylcinnamate, 2-ethylhexyl salicylate and 3,3,5-trimethyl cyclohexyl salicylate.
  • the weight ratio of UV-B filter to 1- (4-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione is between 1: 1 and 10: 1, preferably between 2 : 1 and 8: 1, the molar ratio is between 0.3 and 3.8, preferably between 0.7 and 3.0.
  • the inventively preferred inorganic photoprotective pigments are finely dispersed or colloidally disperse metal oxides and metal salts, for example titanium dioxide, zinc oxide, iron oxide, aluminum oxide, cerium oxide, zirconium oxide, silicates (talc) and barium sulfate.
  • the particles should have an average diameter of less than 100 nm, preferably between 5 and 50 nm and in particular between 15 and 30 nm, so-called nanopigments. They may have a spherical shape, but it is also possible to use those particles which have an ellipsoidal or otherwise deviating shape from the spherical shape.
  • the pigments can also be surface-treated, ie hydrophilized or hydrophobized.
  • Typical examples are coated titanium dioxides, such as. Example, titanium dioxide T 805 (Degussa) or Eusolex ® T2000 (Merck).
  • Suitable hydrophobic coating agents are in particular silicones and in particular trialkoxyoctylsilanes or simethicones. Particularly preferred are titanium dioxide and zinc oxide.
  • the organic UV filter substances are preferably in amounts of 0.1-30% by weight, more preferably 0.5-20% by weight, most preferably 1.0-0.5% by weight and more preferably 3.0 - 10 wt .-%, each based on the total composition included.
  • the inorganic UV filter substances are preferably present in amounts of 0.1-15% by weight, more preferably 0.5-10% by weight, even more preferably 1.0-0.5% by weight and more preferably 2.0 - 4.0 wt .-%, each based on the total composition included.
  • Further inventively particularly preferred cosmetic or dermatological compositions are characterized in that they further contain at least one self-tanning active ingredient.
  • Self-tanning active ingredients preferred according to the invention are selected from dihydroxyacetone, erythrulose and 5,6-dihydroxyindoline.
  • the self-tanning active ingredients are present in a total amount of 0.01-15% by weight, preferably 0.1-10% by weight, more preferably 1.0-0.5% by weight and most preferably 2.0-4. 0 wt .-%, each based on the total composition included.
  • Further inventively particularly preferred cosmetic or dermatological compositions are characterized in that they further contain at least one skin-soothing active ingredient.
  • Skin-soothing active ingredients preferred according to the invention are selected from allantoin, ⁇ -bisabolol, ⁇ -lipoic acid, extracts from Centella asiatica, for example obtainable under the name Madecassicoside from DSM, glycyrrethic acid, which is particularly preferably encapsulated in liposomes and in this form z.
  • phytocohesins sodium beta-sitosteryl
  • the skin-soothing active ingredients are preferably present in a total amount of 0.001-5 wt .-%, particularly preferably 0.01 to 2 wt .-% and most preferably 0.1 to 1 wt .-%, each based on the total composition.
  • Moisturizing active ingredients preferred according to the invention are selected from deoxysugars, more preferably rhamnose and fucose, polysaccharides, which contain at least one deoxy-block, particularly preferably from the commercial products Fucogel ® (INCI name Biosaccharide Gum-1) from Solabia, Rhamnosoft ® (INCI name Biosaccharide Gum-2) from Solabia, Fucogenol ® (INCI name Biosaccharide rubber (3) from Solabia and Glycofilm ® INCI name Biosaccharide Gum-4) from Solabia, further mixtures of the above, at least containing a deoxy-block polysaccharides, for example the mixture of Biosaccharide Gum-2 and Biosaccharide Gum-3, available as a commercial product Elastinol plus ® from Solabia, furthermore urea, N, N'-bis (2-hydroxye
  • the moisturizing active ingredients are preferably present in total amounts of from 0.001 to 10% by weight, more preferably from 0.01 to 5% by weight and most preferably from 0.1 to 1 or 2% by weight, based in each case on the total composition ,
  • compositions are characterized in that they further comprise at least one sebumregulierenden active ingredient.
  • Sebum-regulating active substances which are preferred according to the invention are selected from azelaic acid, sebacic acid, 10-hydroxydecanoic acid, 1,10-decanediol which are used as the triple combination according to the invention in the commercial product acnacidol PG from Vincience, furthermore from the commercial product Azeloglicina (potassium azeloyl diglycinate) from Sinerga, Extracts of Spiraea Ulmaria, as they are eg.
  • the sebum-regulating active ingredients are preferably present in a total amount of 0.001-5% by weight, more preferably 0.01-2% by weight and most preferably 0.1-1% by weight, based in each case on the total composition.
  • compositions according to the invention for the topical treatment of the skin in a suitable cosmetic or dermatological carrier a) at least one soy protein hydrolyzate having an average molecular weight in the range of 1200 to 1800 daltons, preferably in the range of 1400 to 1700 daltons, b) at least a soy protein hydrolyzate having an average molecular weight in the range of 600 to 1000 daltons, preferably 800 daltons, c) at least one wheat protein hydrolyzate and d) at least one hydrophilic extract of ambrette seeds according to any one of claims 1 to 9 are characterized in that they further contain at least one conditioning agent.
  • conditioning substances are to be understood as substances which are absorbed by keratinic materials, in particular on the skin, and improve the physical and sensory properties of both the skin and of the product as such. Conditioners smooth the top layer of the skin and make it soft and supple. Through the choice of conditioning agents (greasy - less greasy, fast or slow spreading, quickly or slowly absorbed into the skin and so on), the skin feel of the entire product can be adjusted.
  • Conditioning agents according to the invention are selected from fatty substances, in particular vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons , Di-n-alkyl ethers having a total of 12 to 36 carbon atoms, z. B.
  • vegetable oils such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons , Di-n-alkyl ethers having a total of 12 to 36 carbon atoms, z.
  • fatty acids especially linear and / or branched, saturated and / or unsaturated C 8 - 3 o fatty acids, fatty alcohols, particularly saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms which may be ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or propoxylated with 3-30, preferably 9-14 propylene oxide units, ester oils, ie esters of C 6 - 3 o-fatty acids with C 2 - 3 o-fatty alcohols, hydroxycarboxylic acid alkyl esters, dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol diol or Propylenglykoldi (2-ethylhexanoate), symmetrical, asymmetrical or cycl
  • glycerol carbonate or dicaprylyl carbonate (Cetiol ® CC)
  • mono, - di- and Trifettklad of saturated and / or unsaturated linear and / or branched fatty acids with glycerol, which are ethoxylated with 1-10, preferably 7-9 ethylene oxide units can, for.
  • Hardened triglyceride fats for example soybean lecithin, egg lecithin and cephalins, silicone compounds selected from decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane and silicone polymers which may, if desired, be cross-linked, e.g. B.
  • polydialkylsiloxanes polyalkylarylsiloxanes, ethoxylated and / or propoxylated polydialkylsiloxanes having the earlier INCI name dimethicone copolyol, and polydialkylsiloxanes containing amine and / or hydroxyl groups, preferably substances with the INCI names Dimethiconol, Amodimethicone or trimethylsilylamodimethicones.
  • the amount of fatty substances used is preferably 0.1-99% by weight, more preferably 2-50% by weight and most preferably 5-20% by weight, in each case based on the total skin treatment agent.
  • the cosmetic or dermatological compositions according to the invention are in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil. or water-in-oil-in-water emulsion, macroemulsion, miniemulsion, microemulsion, PIT emulsion, nanoemulsion, Pickering emulsion, hydrodispersion, a hydrogel, a lipogel, a mono- or multiphase solution, a foam, a powder or a mixture with at least one polymer suitable as a medical adhesive.
  • the agents may also be used in anhydrous form, such as for example, an oil or a balm, be presented.
  • the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • the agents are present as microemulsions.
  • microemulsions are understood as meaning not only the thermodynamically stable microemulsions but also the so-called "PIT" emulsions
  • PIT phase inversion temperature
  • microemulsions are systems with the three components water, oil and emulsifier, which are oil at room temperature
  • PIT phase inversion temperature
  • microemulsions are formed in a certain temperature range (referred to as the phase inversion temperature or "PIT") which, on further heating, converts to water-in-oil emulsions O / W emulsions are also formed, which are also present at room temperature as microemulsions or as very finely divided emulsions having a mean particle diameter of less than 400 nm and in particular of approximately 100 to 300 nm which have a mean particle diameter of about 200 nm.
  • the compositions according to the invention contain at least one surface-active substance as emulsifier or dispersant.
  • Suitable emulsifiers are for example adducts of from 4 to 30 mol ethylene oxide and / or 0 to 5 mol propylene oxide onto linear C 8 -C 22 fatty alcohols, on C 2 -C 22 fatty acids and C 8 -C 5 alkyl phenols, C 2 - C 22 fatty acid monoesters and diesters of addition products of 1 to 30 mol ethylene oxide onto C 3 -C 6 polyols, in particular glycerol, ethylene oxide and polyglycerol plant-delay products onto methyl glucoside fatty acid ester, fatty acid alkanolamides and FettLitereglucami- de, C 8 C 22 alkyl mono- and oligoglycosides and their ethoxylated analogues, with degrees of oligomerization of 1, 1 to 5, in particular 1,
  • compositions according to the invention contain at least one emulsifier, preferably in a total amount of from 0.1 to 25% by weight, more preferably from 0.5 to 15% by weight, based on the total composition.
  • At least one nonionic emulsifier having an HLB value of 8 and below is included.
  • a particularly preferred compound R 1 -O-R 2 is behenyl alcohol.
  • emulsifiers with an HLB value of 8 and below are the adducts of 1 or 2 moles of ethylene oxide or propylene oxide with behenyl alcohol, erucyl alcohol, arachidyl alcohol or behenic acid or erucic acid.
  • the monoesters of Ci 6 -C 30 fatty acids with polyols such as.
  • pentaerythritol trimethylolpropane, diglycerol, sorbitol, glucose or methyl glucose. Examples of such products are z.
  • compositions according to the invention are therefore characterized in that they are present in the form of a lamellar structures oil-in-water emulsion.
  • thickeners for.
  • suitable additives are thickeners, for.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic acid esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with monomers containing sulfonic acid groups. These copolymers can also be present in crosslinked form. Suitable commercial products are NS Sepigel ® 305 Simulgel® ® 600 ® and Simulgel® Simulgel® ® EC SEPPIC. Further particularly preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked polyacrylic acids. Such compounds are for example the commercial products Carbopol ®. A particularly preferred anionic copolymer contains as monomer 80-98% of an unsaturated, optionally substituted C 3 .
  • Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for.
  • polyvinyl alcohols which may be partially saponified, for.
  • Mowiol ® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidone z. B. under the trademark Luviskol ® (BASF) are sold.
  • antioxidants are antioxidants, preservatives, solvents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerol and Diethylene glycol, adsorbents and fillers such as talc and Veegum ®, perfume oils, pigments and dyes for coloring the composition, substances for adjusting the pH, complexing agents such as EDTA, NTA, .beta.-alanine diacetic acid and phosphonic acids, propellants such as propane-butane mixtures, Pentane, isopentane, isobutane, N 2 O, dimethyl ether, CO 2 and air.
  • solvents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerol and Diethylene glycol
  • adsorbents and fillers such as talc and Veegum ®
  • a further subject matter of the present invention is the non-therapeutic, cosmetic use of a cosmetic or dermatological composition for the topical treatment of the skin which is present in a suitable cosmetic or dermatological carrier a) at least one soy protein hydrolyzate having an average molecular weight in the range from 1200 to 1800 daltons, preferably in the range 1400-1700 daltons, b) at least one soy protein hydrolyzate having an average molecular weight in the range of 600-1000 daltons, preferably 800 daltons, c) at least one wheat protein hydrolyzate and d) at least one hydrophilic extract of ambrette seeds according to one of the claims 1 to 9 for the treatment of photodamaged and / or light-aged and / or intrinsically and / or extrinsically aged skin, in particular for anti-wrinkle treatment.
  • the skin firmness and the mechanical stability of the skin can for a z.
  • U F total expandability of the skin under negative pressure
  • a further subject matter of the present invention is the non-therapeutic, cosmetic use of a cosmetic or dermatological composition for the topical treatment of the skin which is present in a suitable cosmetic or dermatological carrier a) at least one soy protein hydrolyzate having an average molecular weight in the range from 1200 to 1800 daltons, preferably in the range from 1400 to 1700 daltons, b) at least one soy protein hydrolyzate having an average molecular weight in the range from 600 to 1000 daltons, preferably 800 daltons, c) at least one wheat protein hydrolyzate and d) at least one hydrophilic extract
  • Ambrette seed according to one of the claims 1 - 9 contains, for the treatment of light-damaged and / or light-aged and / or intrinsically and / or extrinsically aged skin, in particular for anti-wrinkle treatment.
  • to increase the skin firmness and / or to improve the mechanical stability of the skin and / or to increase the skin elasticity and / or skin firmness and / or to improve the skin softness and smoothness to smooth the skin and / or to reduce wrinkles, wrinkles and / or fine lines and / or to improve the appearance of the skin, protect and / or prevent extrinsic skin aging and / or delay extrinsic skin aging, retard intrinsic skin aging, treat age spots, maintain normal protein metabolism the skin, to reduce oxidative damage in the skin and / or to improve the skin compatibility of skin treatment agents with anti-aging effect, in particular anti-wrinkle agents.
  • Another object of the present invention is a non-therapeutic method for the non-therapeutic, cosmetic treatment of photodamaged and / or light-aged and / or intrinsically and / or extrinsically aged skin, in particular for anti-wrinkle treatment, to increase the skin firmness and / or to improve the mechanical Stability of the skin and / or to increase the elasticity of the skin and / or the firmness of the skin and / or to improve the softness and smoothness of the skin, to smooth the skin and / or to reduce wrinkles, wrinkles and / or fine lines and / or to improve the visual appearance Appearance of the skin, for the protection and / or prophylaxis of extrinsic skin aging and / or retarding extrinsic skin aging, retarding intrinsic skin aging, treating age spots, maintaining normal protein metabolism of the skin, reducing oxidative damage in the skin the skin and / or to improve the skin compatibility of skin treatment compositions with anti-aging effect, in particular anti-wrinkle agents, which is

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des compositions topiques cosmétiques ou dermatologiques pour le traitement des peaux matures ou des peaux présentant un vieillissement intrinsèque ou extrinsèque, en particulier pour le traitement antiride. Les compositions selon l'invention contiennent, dans un véhicule cosmétique ou dermatologique acceptable, une combinaison d'au moins un hydrolysat de protéines de soja ayant un poids moléculaire moyen compris entre 1200 et 1800 daltons, d'au moins un hydrolysat de protéines de soja ayant un poids moléculaire moyen compris entre 600 et 1000 daltons, d'au moins un hydrolysat de protéines de blé, ainsi que d'un extrait hydrophile de graines d'ambrette.
EP09740708A 2008-10-31 2009-10-28 Combinaison de principes actifs pour le traitement des peaux matures Ceased EP2346487A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008054118A DE102008054118A1 (de) 2008-10-31 2008-10-31 Wirkstoffkombination zur Behandlung reifer Haut I
PCT/EP2009/064232 WO2010049457A2 (fr) 2008-10-31 2009-10-28 Combinaison de principes actifs pour le traitement des peaux matures

Publications (1)

Publication Number Publication Date
EP2346487A2 true EP2346487A2 (fr) 2011-07-27

Family

ID=41429336

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09740708A Ceased EP2346487A2 (fr) 2008-10-31 2009-10-28 Combinaison de principes actifs pour le traitement des peaux matures

Country Status (3)

Country Link
EP (1) EP2346487A2 (fr)
DE (1) DE102008054118A1 (fr)
WO (1) WO2010049457A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6153469B2 (ja) * 2011-09-12 2017-06-28 ロート製薬株式会社 ダイズタンパク質の加水分解物を含有する組成物
EP2845583B1 (fr) 2013-09-04 2016-11-09 PM-International AG Produit de lifting cosmétique
US9248160B1 (en) * 2015-07-28 2016-02-02 Zo Skin Health, Inc. Post-procedure skin care systems, compositions, and methods of use thereof
EP3165216A1 (fr) * 2015-11-05 2017-05-10 Basf Se Composition texturee
BR112018015897B1 (pt) 2016-02-04 2022-03-03 Alastin Skincare, Inc Composição tópica anidra para promover a reparação da pele, composições tópicas para promover a restauração da pele, composição tópica para aliviar contusões causadas por um procedimento cosmético e uso das mesmas
FR3052666B1 (fr) * 2016-06-16 2021-07-30 Laboratoires M&L Composition cosmetique comprenant un extrait d'amande douce et procede de soin
KR102757675B1 (ko) 2017-08-03 2025-01-20 앨러스틴 스킨케어, 인크. 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법
CH714167B1 (de) 2018-02-01 2019-03-15 La Prairie Group Ag Wirkstoffkomplex für kosmetische Zubereitungen.
US11103455B2 (en) 2018-08-02 2021-08-31 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
CN111714400A (zh) * 2020-07-27 2020-09-29 广东真丽斯化妆品有限公司 一种具有抗衰修复作用的化妆品及其制备方法
BR112023024114A2 (pt) 2021-05-20 2024-02-06 Roc Opco Llc Composições cosméticas que contêm compostos de vitamina c e usos das mesmas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE357273T1 (de) * 2000-08-10 2007-04-15 Henkel Kgaa Kosmetische mittel enthaltend malvaceae- samenextrakte
DE10163246A1 (de) 2001-12-21 2003-07-10 Henkel Kgaa Neue Verwendung von Apfelkernextrakten in kosmetischen oder pharmazeutischen Zusammensetzung
EP1640041A3 (fr) * 2004-09-24 2006-05-24 Henkel Kommanditgesellschaft auf Aktien composition cosmétique ou dermatologique pour le traitement du vieillissement de la peau ou pour le traitement de la peau endommagée par la lumière
KR20060087817A (ko) * 2005-01-31 2006-08-03 주식회사 태평양 항노화용 화장료 조성물
DE102006046076A1 (de) * 2005-10-14 2007-04-19 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
DE102005063062A1 (de) * 2005-12-29 2007-07-05 Henkel Kgaa Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
DE102005063179A1 (de) * 2005-12-30 2006-09-28 Henkel Kgaa Verwendung von Vitamin B6 zur Behandlung der Hautalterung
WO2008029064A2 (fr) * 2006-09-06 2008-03-13 Thorel Jean-Noel Utilisation topique d'un extrait peptidique de soja et/ou de ble comme agent photoprotecteur
FR2907014B1 (fr) * 2006-10-17 2009-05-15 Engelhard Lyon Sa Utilisation d'actifs cosmetiques pour proteger le fibroblaste growth factor-beta ou fgf-2 de la matrice extracellulaire dans le but de restructurer cette matrice
FR2929511B1 (fr) * 2008-04-02 2010-12-31 Basf Beauty Care Solutions France Sas Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010049457A2 *

Also Published As

Publication number Publication date
DE102008054118A1 (de) 2010-05-06
WO2010049457A2 (fr) 2010-05-06
WO2010049457A3 (fr) 2011-04-28

Similar Documents

Publication Publication Date Title
EP2346487A2 (fr) Combinaison de principes actifs pour le traitement des peaux matures
EP1640041A2 (fr) composition cosmétique ou dermatologique pour le traitement du vieillissement de la peau ou pour le traitement de la peau endommagée par la lumière
DE102005063062A1 (de) Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
DE102004055541A1 (de) Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
EP2005941A2 (fr) Compositions rajeunissant les cellules
EP2451434A2 (fr) Combinaison de substances actives pour le traitement d'une peau mature ii
EP1938789A1 (fr) Amélioration de la tolérance de la peau aux agents actifs hyperémiants
DE102011089612A1 (de) Körperpflegemittel mit verbesserter Hautfeuchte
WO2006018198A1 (fr) Compositions cosmetiques et dermatologiques a base de (2-hydroxyethyl)uree
DE102008061045A1 (de) Verwendung von epsilon-Viniferin
DE102011084904A1 (de) Hautstraffende kosmetische Zusammensetzungen mit verbessertem Hautgefühl
DE102009045981A1 (de) Antifalten-Kosmetikum mit Strandkamillenextrakt
DE102006062438A1 (de) Kosmetische Zusammensetzungen zur Glättung und Straffung der Haut
DE102009027199A1 (de) UV-Schutz-Kosmetikum
EP1938785A2 (fr) Emulsions huile dans l'eau cosmétiques et dermatologiques dotées de propriétés auto-conservatrices
DE102005063179A1 (de) Verwendung von Vitamin B6 zur Behandlung der Hautalterung
DE102009037537A1 (de) Antifalten-Kosmetikum
EP1803435B1 (fr) Compositions cosmétiques dotées d'une protection contre les rayonnements solaires sur la base d'émulsions lamellaires
DE102007031452A1 (de) Feuchtigkeitsspendende kosmetische und dermatologische Zusammensetzungen mit Enhancern
DE102008061340A1 (de) Antioxidative Zusammensetzungen
DE102008061044A1 (de) Zusammensetzung mit antioxidativ wirksamen Peptiden
EP2633887B1 (fr) Combinaison de principes actifs d'un nouveau type pour une action anti-plis efficace
DE102009039393A1 (de) Antifalten-Kosmetikum mit einem Extrakt aus Sommer-Knotenblumen
DE102008025089A1 (de) Zellverjüngende Zusammensetzungen
EP1799311A2 (fr) Compositions comprenant des inhibiteurs de la synthese de la prostaglandine et/ou du leucotriene en combinaison avec des stimulateurs de liberation de neuromediateurs cutanes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110511

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130603

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160324